Bessemer Group Inc. Has $2.54 Million Stock Position in HCA Healthcare, Inc. (NYSE:HCA)

Bessemer Group Inc. raised its stake in HCA Healthcare, Inc. (NYSE:HCA) by 51.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,629 shares of the company’s stock after buying an additional 2,584 shares during the period. Bessemer Group Inc.’s holdings in HCA Healthcare were worth $2,543,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in HCA. Atlantic Edge Private Wealth Management LLC acquired a new position in shares of HCA Healthcare during the fourth quarter worth $27,000. LifeSteps Financial Inc. acquired a new position in shares of HCA Healthcare during the first quarter worth $33,000. Northwest Investment Counselors LLC acquired a new position in shares of HCA Healthcare during the first quarter worth $36,000. Rise Advisors LLC acquired a new position in shares of HCA Healthcare during the first quarter worth $36,000. Finally, Activest Wealth Management acquired a new position in shares of HCA Healthcare during the first quarter worth $40,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on HCA. JPMorgan Chase & Co. lifted their target price on shares of HCA Healthcare from $327.00 to $332.00 and gave the stock a “neutral” rating in a research note on Thursday, May 30th. Truist Financial lifted their target price on shares of HCA Healthcare from $375.00 to $390.00 and gave the stock a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and set a $335.00 target price on shares of HCA Healthcare in a research note on Wednesday. StockNews.com raised shares of HCA Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 1st. Finally, TD Cowen decreased their price target on shares of HCA Healthcare from $371.00 to $360.00 and set a “buy” rating for the company in a research note on Tuesday, April 30th. Four research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $339.72.

Insider Buying and Selling

In related news, SVP Kathryn A. Torres sold 1,863 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $326.18, for a total transaction of $607,673.34. Following the sale, the senior vice president now owns 19,612 shares of the company’s stock, valued at approximately $6,397,042.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Kathryn A. Torres sold 973 shares of HCA Healthcare stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $312.00, for a total value of $303,576.00. Following the transaction, the senior vice president now owns 22,365 shares in the company, valued at approximately $6,977,880. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Kathryn A. Torres sold 1,863 shares of HCA Healthcare stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $326.18, for a total transaction of $607,673.34. Following the completion of the transaction, the senior vice president now owns 19,612 shares in the company, valued at approximately $6,397,042.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,397 shares of company stock valued at $3,921,929. Company insiders own 1.60% of the company’s stock.

HCA Healthcare Stock Performance

HCA traded up $9.67 during midday trading on Thursday, reaching $353.61. The company had a trading volume of 475,600 shares, compared to its average volume of 1,147,719. The stock has a market cap of $92.61 billion, a PE ratio of 17.15, a P/E/G ratio of 1.45 and a beta of 1.68. The company has a debt-to-equity ratio of 29.26, a quick ratio of 1.02 and a current ratio of 1.16. The business has a 50-day moving average price of $328.88 and a two-hundred day moving average price of $322.41. HCA Healthcare, Inc. has a 12-month low of $215.96 and a 12-month high of $355.88.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported $5.50 EPS for the quarter, beating analysts’ consensus estimates of $4.97 by $0.53. The company had revenue of $17.49 billion for the quarter, compared to analysts’ expectations of $17.05 billion. HCA Healthcare had a net margin of 8.40% and a return on equity of 621.57%. HCA Healthcare’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $4.29 EPS. On average, sell-side analysts expect that HCA Healthcare, Inc. will post 22.2 earnings per share for the current fiscal year.

HCA Healthcare Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 16th will be issued a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date is Monday, September 16th. HCA Healthcare’s dividend payout ratio (DPR) is presently 13.16%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.